SCHEMBL4246773

SCHEMBL4246773

Cc1ncc(-c2nc(Nc3ccc(N4CCNCC4)cn3)ncc2F)n1C1CCCC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 18/20 0.62
CCND1 P24385 14/20 0.62
CDK6 Q00534 9/20 0.62
CCND3 P30281 8/20 0.62
CCNA2 P20248 7/20 0.62
CDK2 P24941 7/20 0.62
CDK1 P06493 3/20 0.62
CCNB1 P14635 3/20 0.62
CCNT1 O60563 2/20 0.62
CDK7 P50613 2/20 0.62
CDK9 P50750 2/20 0.62
CCNH P51946 2/20 0.62
CCND2 P30279 6/20 0.62
CCNA1 P78396 3/20 0.60
PIM1 P11309 1/20 0.59
FGFR1 P11362 3/20 0.59
FGFR2 P21802 3/20 0.59
FGFR4 P22455 3/20 0.59
FGFR3 P22607 3/20 0.59
FLT3 P36888 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4247804 0.89 CDK4 (0.62) CDK4CCND1CDK6CCND3CCNA2
SCHEMBL3549603 0.87 CDK4 (0.59) CDK4CCND1CDK6CCND3CCNA2
SCHEMBL4245323 0.84 CDK4 (0.62) CDK4CCND1CDK6CCND3CCNA2
SCHEMBL4248478 0.83 CDK4 (0.54) CDK4CCND1CDK6CCND3CCNA2
SCHEMBL21161074 0.79 CDK4 (0.66) CDK4CCND1CDK6CCND3CCNA2
SCHEMBL30237278 0.78 CDK4 (0.61) CDK4CCND1CDK6CCND3CCNA2
SCHEMBL29250049 0.78 CDK4 (0.61) CDK4CCND1CDK6CCND3CCNA2
SCHEMBL3554221 0.77 CDK2 (0.70) CDK4CCND1CDK6CCND3CCNA2
SCHEMBL18453323 0.77 CDK4 (1.00) CDK4CCND1CDK6CCND3CCNA2
SCHEMBL29815852 0.77 CDK4 (1.00) CDK4CCND1CDK6CCND3CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233928-A1 IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2009-09-17 US disclosed
EP-1869016-A1 IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION AstraZeneca AB (SE) 2007-12-26 EP disclosed
WO-2006095159-A1 (IMIDAZOLO-5-YL)-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233928-A1 IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION MKI67, TYMP, PCNA CDK4 30/4885CCND1 38/4885CDK6 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.